Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.

Oncogene - 1 Jul 2018

Reyes-Uribe Patricia, Adrianzen-Ruesta Maria Paz, Deng Zhong, Echevarria-Vargas Ileabett, Mender Ilgen, Saheb Steven, Liu Qin, Altieri Dario C, Murphy Maureen E, Shay Jerry W, Lieberman Paul M, Villanueva Jessie

Abstract excerpt

Targeting RAS is one of the greatest challenges in cancer therapy. Oncogenic mutations in NRAS are present in over 25% of melanomas and patients whose tumors harbor NRAS mutations have limited therapeutic options and poor prognosis. Thus far, there are no clinical agents available to effectively target NRAS or any other RAS oncogene. An alternative approach is to identify and target critical tumor vulnerabilities...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to GTP Phosphohydrolases
Share to Antioxidants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Reactive Oxygen Species

Share to Telomerase

Share to Up-Regulation

Source

Open in PubMed Open full text

Identifiers

PMID: 29695835
DOI: 10.1038/s41388-018-0247-7
PMCID: PMC6062502

Genes

NRAS
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.PMID 29695835Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic ApoptosisSemantic proximity Read ↗

Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping ReviewSemantic proximity Read ↗

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.Semantic proximity Read ↗

Inhibition of the Myocardin-Related Transcription Factor pathway increases efficacy of Trametinib in NRAS-mutant melanoma cell linesSemantic proximity Read ↗

Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.Semantic proximity Read ↗

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanomaSemantic proximity Read ↗

TERT Promoter Mutations and Telomerase in MelanomaSemantic proximity Read ↗

NRAS mutant melanoma--undrugable?Semantic proximity Read ↗

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.Semantic proximity Read ↗

A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanomaSemantic proximity Read ↗

Nras in melanoma: targeting the undruggable target.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.